Author: Risner, Kenneth H.; Tieu, Katie V.; Wang, Yafei; Bakovic, Allison; Alem, Farhang; Bhalla, Nishank; Nathan, Steven; Conway, Daniel E.; Macklin, Paul; Narayanan, Aarthi
Title: Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture Cord-id: 67t2q5ud Document date: 2020_8_13
ID: 67t2q5ud
Snippet: In an effort to identify therapeutic intervention strategies for the treatment of COVID-19, we have investigated a selection of FDA-approved small molecules and biologics that are commonly used to treat other human diseases. A screen of 19 small molecules and 3 biologics was conducted in cell culture and the impact of treatment on viral titer was quantified by plaque assay. The screen identified 4 FDA-approved small molecules, Maraviroc, FTY720 (Fingolimod), Atorvastatin and Nitazoxanide that we
Document: In an effort to identify therapeutic intervention strategies for the treatment of COVID-19, we have investigated a selection of FDA-approved small molecules and biologics that are commonly used to treat other human diseases. A screen of 19 small molecules and 3 biologics was conducted in cell culture and the impact of treatment on viral titer was quantified by plaque assay. The screen identified 4 FDA-approved small molecules, Maraviroc, FTY720 (Fingolimod), Atorvastatin and Nitazoxanide that were able to inhibit SARS-CoV-2 infection. Confocal microscopy with over expressed S protein demonstrated that Maraviroc reduced the extent of S-protein mediated cell fusion as observed by fewer multinucleate cells in drug-treated cells. Mathematical modeling of drug-dependent viral multiplication dynamics revealed that prolonged drug treatment will exert an exponential decrease in viral load in a multicellular/tissue environment. Taken together, the data demonstrate that Maraviroc, Fingolimod, Atorvastatin and Nitazoxanide inhibit SARS-CoV-2 in cell culture.
Search related documents:
Co phrase search for related documents- abl kinase and acute respiratory: 1, 2, 3, 4, 5, 6, 7
- abl kinase and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
- abl kinase inhibitor and acute respiratory: 1, 2, 3
- abl kinase inhibitor and acute respiratory syndrome: 1, 2, 3
- absence presence and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- absence presence and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- absence presence and acute respiratory virus: 1, 2, 3, 4, 5
- absence presence and addition step: 1, 2
- absence presence and additional role: 1, 2
- absence presence and additional role play: 1
- absence presence and additional study: 1, 2, 3, 4
- absence presence and low concentration: 1, 2, 3
- absence presence and luciferase assay: 1
- absence presence and luciferase expression: 1
- absence presence and luciferase reporter: 1, 2, 3, 4, 5
- absence presence and lung damage: 1, 2
- absence presence and lymphoid tissue: 1, 2, 3, 4
- absence presence and magnesium calcium: 1
Co phrase search for related documents, hyperlinks ordered by date